---
name: GemPharmatech
slug: gempharmatech
site: cro
website_domain: gempharmatech.com
summary: GemPharmatech develops and supplies genetically engineered mouse models (GEMMs) and preclinical research services using CRISPR/Cas9 and gene-editing technologies, with a library of 25,000+ mouse strains including KO/cKO, humanized, and immunodeficient models. Headquartered in China.
tagline: Global leader in genetically engineered mouse models and preclinical research services.
founded_year: 2017
employee_count_band: 1001-5000
employee_count_label: 1,001–5,000
parent_name: 
parent_slug: 
hq_country: CN
tier2_domain_verified: false
updated_at: 2026-07-23T00:02:34.085Z
services_count: 7
modalities_count: 1
indications_count: 7
locations_count: 1
review_signal_gate: closed
generated_by: BioBM Editorial AI
---

# GemPharmatech

Global leader in genetically engineered mouse models and preclinical research services.

Listed on cro.directory.

## Summary

GemPharmatech develops and supplies genetically engineered mouse models (GEMMs) and preclinical research services using CRISPR/Cas9 and gene-editing technologies, with a library of 25,000+ mouse strains including KO/cKO, humanized, and immunodeficient models. Headquartered in China.

## At a glance

- Founded: 2017
- Employees (est.): 1,001–5,000
- HQ country: CN

## Services

- Specialized & Large-Animal Models
- In Vivo PK / PD Studies
- In Vivo Efficacy Models
- Preclinical In Vivo Studies
- In Vitro Pharmacology
- Preclinical In Vitro Studies
- Target Identification & Validation

## Modalities

- Biologics (Monoclonal Antibodies)

## Indications

- Oncology
- Metabolic
- Cardiovascular
- Immunology
- Neurology
- Infectious Disease
- Rare Disease

## Locations

- Headquarters, Jiangsu, China

## Long description

## Overview

GemPharmatech is a leading provider of genetically engineered mouse models (GEMMs) and preclinical research services to global pharmaceutical, biotech, and research organizations. Founded in 2017, the company specializes in developing animal models using cutting-edge gene-editing technologies including CRISPR/Cas9 and ES cell targeting.

## Core Capabilities

**Model Development & Resources:**
- Library of 25,000+ mouse strains with ~30,000 proprietary genetically modified models
- Conditional knockout (cKO) and knockout (KO) mouse models ("Spotted Mouse Program")
- Humanized mouse models (gene humanization, cellular/tissue humanization, immune reconstitution, microbiota humanization)
- Immunodeficient mouse strains including NCG mice (T cell, B cell, NK cell deficient)
- Germ-free mouse strains
- NeoMab® fully human antibody transgenic mice for antibody drug discovery
- Wild-derived mouse models from diverse geographic origins
- Disease models covering 1,000+ validated phenotypes across oncology, metabolic, cardiovascular, autoimmune, neurological, hematological, and rare disease areas

**Technical Services:**
- Custom gene editing (transgenic, KO, KI, point mutation)
- Custom breeding services (biocleaning, assisted reproduction, genetic material cryopreservation, surrogate breeding)
- Quality control testing (microbial detection, SNP genotyping)
- Animal facility management and housing
- Preclinical pharmacology and efficacy evaluation (in vitro and in vivo)
- Target validation and non-GLP safety assessment

## Infrastructure

- 6,000+ annual model generation capacity
- 230,000+ SPF cage capacity
- 30,000+ square meters of SPF facilities
- 1,700+ employees globally
- 10 global headquarters and subsidiary locations
- Designated as a co-builder of the National Genetic Engineering Mouse Resource Library by China's Ministry of Science and Technology

## Disease Focus Areas

Oncology, metabolic and cardiovascular disease, autoimmune disease, neurodegeneration, infectious disease, and rare disease.

## Related companies

- [Cyagen Biosciences](/companies/cyagen) (Specialized & Large-Animal Models, In Vivo Efficacy Models) — [Compare](/compare/cyagen/gempharmatech)
- [BioLegacy Research](/companies/biolegacy) (Specialized & Large-Animal Models, In Vivo PK / PD Studies) — [Compare](/compare/biolegacy/gempharmatech)
- [Cyagen Biosciences](/companies/apac-cyagen) (Specialized & Large-Animal Models, In Vivo Efficacy Models) — [Compare](/compare/apac-cyagen/gempharmatech)
- [Reaction Biology](/companies/reactionbiology) (Specialized & Large-Animal Models, In Vivo PK / PD Studies) — [Compare](/compare/gempharmatech/reactionbiology)
- [PharmaLegacy Laboratories](/companies/pharmalegacy) (Specialized & Large-Animal Models, In Vivo PK / PD Studies) — [Compare](/compare/gempharmatech/pharmalegacy)
- [Cardiomedex](/companies/cardiomedex) (In Vivo Efficacy Models, Preclinical In Vivo Studies) — [Compare](/compare/cardiomedex/gempharmatech)
- [BioDuro-Sundia](/companies/bioduro-sundia) (Specialized & Large-Animal Models, In Vivo PK / PD Studies) — [Compare](/compare/bioduro-sundia/gempharmatech)
- [Creative Diagnostics](/companies/antiviral) (In Vivo Efficacy Models, Preclinical In Vivo Studies) — [Compare](/compare/antiviral/gempharmatech)

_Profile last updated: 2026-07-23T00:02:34.085Z. Profile facts may include AI-assisted enrichment._

Auto-generated by BioBM Editorial AI for machine-readable profile access.